In people with heart disease taking moderate-dose statins, rosuvastatin, pravastatin, and simvastatin are linked to a slightly higher chance of developing diabetes over five years than atorvastatin, even though all these drugs protect the heart equally well.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of randomized trials comparing rosuvastatin, pravastatin, simvastatin, and atorvastatin in secondary prevention populations could determine whether observed diabetes risk differences are consistent across studies and generalizable.
A systematic review and meta-analysis of all published randomized controlled trials comparing rosuvastatin, pravastatin, simvastatin, and atorvastatin at moderate intensity in adults with established ASCVD, including at least 10,000 participants total, with diabetes incidence as a prespecified secondary outcome, and follow-up of at least 2 years.
A randomized trial could determine whether switching from atorvastatin to rosuvastatin, pravastatin, or simvastatin directly increases diabetes incidence in high-risk patients, independent of confounding.
A double-blind, placebo-controlled RCT of 2,000 adults aged 55–75 with established ASCVD and fasting glucose 90–125 mg/dL, randomized 1:1:1:1 to moderate-intensity rosuvastatin (10 mg), pravastatin (40 mg), simvastatin (20 mg), or atorvastatin (20 mg) for 3 years, with primary outcome being new-onset diabetes defined by HbA1c ≥6.5% or initiation of antidiabetic medication.
A prospective cohort with detailed metabolic phenotyping could confirm whether the observed association persists after accounting for unmeasured confounders like diet, physical activity, and prediabetes status.
A prospective cohort of 5,000 adults with ASCVD initiating moderate-intensity statins, with baseline and annual measurements of insulin sensitivity, beta-cell function, adipokines, diet, physical activity, and body composition, followed for 5 years to assess diabetes incidence by statin type.
A case-control study could identify whether specific metabolic profiles at baseline predict higher diabetes risk with certain statins, helping to stratify risk.
A case-control study comparing 500 patients with new-onset diabetes after 2 years on moderate-intensity statins to 500 matched controls without diabetes, assessing baseline insulin resistance, liver fat, and genetic variants in SLCO1B1 and ABCG2, stratified by statin type.
A cross-sectional analysis could reveal whether current statin type correlates with HbA1c levels in a population with established ASCVD, but cannot determine causality.
A cross-sectional analysis of 10,000 adults with ASCVD on moderate-intensity statins, measuring HbA1c, fasting glucose, and insulin levels at a single time point, stratified by statin type and adjusted for BMI and duration of therapy.